CRISPR Therapeutics AG (CRSP) Other Non-Current Assets (2015 - 2026)

CRISPR Therapeutics AG has disclosed Other Non-Current Assets across 12 years of filings, most recently posting $37.7 million for Q2 2026.

• In Q2 2026, Other Non-Current Assets rose 371.03% year-over-year to $37.7 million; the TTM figure through Jun 2026 stood at $37.7 million (up 371.03% YoY), while the FY2025 annual figure was $24.4 million, up 53.95% from the prior year.
• Other Non-Current Assets came in at $37.7 million for Q2 2026 at CRISPR Therapeutics AG, up from $29.0 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $37.7 million in Q2 2026 to a low of $8.0 million in Q1 2025.
• Average Other Non-Current Assets over 5 years is $15.4 million, with a median of $11.8 million recorded in 2023.
• Year-over-year, Other Non-Current Assets tumbled 32.91% in 2022 and surged 371.03% in 2026.
• Over 5 years, Other Non-Current Assets stood at $11.6 million in 2022, then retreated by 0.38% to $11.6 million in 2023, then jumped by 36.56% to $15.8 million in 2024, then jumped by 53.95% to $24.4 million in 2025, then jumped by 54.76% to $37.7 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $37.7 million in Q2 2026, $29.0 million in Q1 2026, and $24.4 million in Q4 2025.